Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Shimada

Showing results (211-220 of 295) with videos related to

Pageof 30
Sort By:
Anticancer Research|April 4, 2021
Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib TreatmentYusuke Niisato, Toshikazu Moriwaki, Shota Fukuoka, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|March 2, 2016
Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal CarcinomatosisYusuke Sasaki, Tetsuya Hamaguchi, Yasuhide Yamada, et al.
Global Health & Medicine|December 17, 2020
Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trialYasuhide Yamada, Kei Muro, Keiichi Takahashi, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2013
Structure-activity relationship study of phenylpyrazole derivatives as a novel class of anti-HIV agentsTsukasa Mizuhara, Takayuki Kato, Atsushi Hirai, et al.
Japanese Journal of Clinical Oncology|August 27, 2014
A randomized controlled trial comparing laparoscopic surgery with open surgery in palliative resection of primary tumor in incurable Stage IV colorectal cancer: Japan Clinical Oncology Group Study JCOG 1107 (ENCORE trial)Masafumi Inomata, Tomonori Akagi, Hiroshi Katayama, et al.
Cancer Chemotherapy and Pharmacology|October 1, 2014
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapyTsuyoshi Shirakawa, Ken Kato, Kengo Nagashima, et al.
Communications Medicine|May 7, 2026
Sequential versus upfront oxaliplatin-based therapy in metastatic colorectal cancer: long-term outcomes of a randomized phase 3 trialMakoto Okawaki, Mototsugu Shimokawa, Ryo Inada, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 31, 2004
[Molecule based diagnosis]Hideyuki Akaza, Tomohiko Ichikawa, Takashi Tsuruo, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 15, 2018
FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer CellsShinji Mima, Chihaya Kakinuma, Tamami Higuchi, et al.
Cancer Chemotherapy and Pharmacology|July 21, 2016
A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumabNaoki Takahashi, Satoru Iwasa, Masaru Fukahori, et al.
Pageof 30

Showing results (211-220 of 295) with videos related to

Sort By:
Pageof 30
Anticancer Research|April 4, 2021
Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib TreatmentYusuke Niisato, Toshikazu Moriwaki, Shota Fukuoka, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|March 2, 2016
Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal CarcinomatosisYusuke Sasaki, Tetsuya Hamaguchi, Yasuhide Yamada, et al.
Global Health & Medicine|December 17, 2020
Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trialYasuhide Yamada, Kei Muro, Keiichi Takahashi, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2013
Structure-activity relationship study of phenylpyrazole derivatives as a novel class of anti-HIV agentsTsukasa Mizuhara, Takayuki Kato, Atsushi Hirai, et al.
Japanese Journal of Clinical Oncology|August 27, 2014
A randomized controlled trial comparing laparoscopic surgery with open surgery in palliative resection of primary tumor in incurable Stage IV colorectal cancer: Japan Clinical Oncology Group Study JCOG 1107 (ENCORE trial)Masafumi Inomata, Tomonori Akagi, Hiroshi Katayama, et al.
Cancer Chemotherapy and Pharmacology|October 1, 2014
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapyTsuyoshi Shirakawa, Ken Kato, Kengo Nagashima, et al.
Communications Medicine|May 7, 2026
Sequential versus upfront oxaliplatin-based therapy in metastatic colorectal cancer: long-term outcomes of a randomized phase 3 trialMakoto Okawaki, Mototsugu Shimokawa, Ryo Inada, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 31, 2004
[Molecule based diagnosis]Hideyuki Akaza, Tomohiko Ichikawa, Takashi Tsuruo, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 15, 2018
FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer CellsShinji Mima, Chihaya Kakinuma, Tamami Higuchi, et al.
Cancer Chemotherapy and Pharmacology|July 21, 2016
A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumabNaoki Takahashi, Satoru Iwasa, Masaru Fukahori, et al.
Pageof 30